PMID- 35870176
OWN - NLM
STAT- MEDLINE
DCOM- 20220909
LR  - 20220912
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 45
IP  - 9
DP  - 2022 Sep
TI  - Initiating ivabradine during hospitalization in patients with acute heart 
      failure: A real-world experience in China.
PG  - 928-935
LID - 10.1002/clc.23880 [doi]
AB  - BACKGROUND: Initiating ivabradine in acute heart failure (HF) is still 
      controversial. HYPOTHESIS: Ivabradine might be effective to be added in acute but 
      hemodynamically stable HF. METHODS: A retrospective cohort of hemodynamically 
      stable acute HF patients was enrolled from January 2018 to January 2020 and 
      followed until July 2020. The primary endpoints were all-cause mortality and 
      rehospitalization for HF. Secondary endpoints included heart rate (HR), cardiac 
      function measured by New York Heart Association (NYHA) class, and left 
      ventricular ejection fraction (LVEF) and adverse events, which were compared 
      between patients with or without ivabradine. RESULTS: A total of 126 patients 
      were enrolled (50 males, median age 54 years, 81% with decompensated HF, median 
      follow-up of 9 months). In patients treated with ivabradine, although baseline 
      HRs were higher than the reference group (96 vs. 80 bpm), they were comparable 
      after 3 months; more patients tolerated high doses of beta-blockers (27% vs. 7.9%), 
      improved to NYHA class I function (55.6% vs. 23.8%) and exhibited normal LVEFs 
      (37.8% vs. 14.3%) than the reference group (all p < .05). Ivabradine was 
      associated with a significant reduction of rehospitalization for HF than the 
      reference group (25.4% vs.61.9%), with longer event-free survival times (hazard 
      ratio: 0.45, 95% confidence interval [CI]: 0.25-0.79), and was related with 
      primary endpoints negatively (hazard ratio 0.51, 95% CI: 0.28-0.91) (all 
      p < .05). CONCLUSION: In patients with acute but hemodynamically stable HF, 
      ivabradine may significantly reduce HR, improve cardiac function, and reduce HF 
      rehospitalization.
CI  - (c) 2022 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
FAU - Liu, Ying-Xian
AU  - Liu YX
AUID- ORCID: 0000-0003-1155-7130
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Chen, Wei
AU  - Chen W
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Lin, Xue
AU  - Lin X
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Zhu, Yan-Lin
AU  - Zhu YL
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Lai, Jing-Zhi
AU  - Lai JZ
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Li, Jin-Yi
AU  - Li JY
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Guo, Xiao-Xiao
AU  - Guo XX
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Yang, Jing
AU  - Yang J
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Qian, Hao
AU  - Qian H
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Zhu, Yuan-Yuan
AU  - Zhu YY
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Wu, Wei
AU  - Wu W
AUID- ORCID: 0000-0002-9044-0901
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
FAU - Fang, Li-Gang
AU  - Fang LG
AUID- ORCID: 0000-0002-3980-3682
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
LA  - eng
GR  - 82000470/National Natural Science Foundation of China/
GR  - 2019-I2M-2-003/Chinese Academy of Medical Sciences Innovation Fund for Medical 
      Sciences/
PT  - Journal Article
DEP - 20220723
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Benzazepines)
RN  - 0 (Cardiovascular Agents)
RN  - 3H48L0LPZQ (Ivabradine)
SB  - IM
MH  - Benzazepines/adverse effects
MH  - *Cardiovascular Agents/adverse effects
MH  - *Heart Failure/diagnosis/drug therapy
MH  - Heart Rate
MH  - Hospitalization
MH  - Humans
MH  - Ivabradine/pharmacology/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Stroke Volume/physiology
MH  - Treatment Outcome
MH  - Ventricular Function, Left/physiology
PMC - PMC9451666
OTO - NOTNLM
OT  - acute heart failure
OT  - ivabradine
OT  - outcome
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/24 06:00
MHDA- 2022/09/11 06:00
PMCR- 2022/07/23
CRDT- 2022/07/23 15:12
PHST- 2022/06/01 00:00 [revised]
PHST- 2022/02/05 00:00 [received]
PHST- 2022/06/08 00:00 [accepted]
PHST- 2022/07/24 06:00 [pubmed]
PHST- 2022/09/11 06:00 [medline]
PHST- 2022/07/23 15:12 [entrez]
PHST- 2022/07/23 00:00 [pmc-release]
AID - CLC23880 [pii]
AID - 10.1002/clc.23880 [doi]
PST - ppublish
SO  - Clin Cardiol. 2022 Sep;45(9):928-935. doi: 10.1002/clc.23880. Epub 2022 Jul 23.